

Getting Started With **ADSTILADRIN**

For high-risk NMIBC
when BCG does not work

STIL DOING IT MY WAY With **ADSTILADRIN**

A unique treatment that may
help you keep your bladder

What's your way?

Not actual ADSTILADRIN patients.

INDICATION

ADSTILADRIN is a treatment for adults who have all the following:

- High-risk non-muscle-invasive bladder cancer (NMIBC)
- Cancer that is not responding to Bacillus Calmette-Guérin (BCG) therapy
- Carcinoma in situ (CIS) with or without other high-grade tumors

Please see **Important Safety Information**
on **page 11** and full **Prescribing Information**.

 **ADSTILADRIN**[®]
(nadofaragene firadenovec-vncg)
suspension, for intravesical use / 3×10^{11} viral particles/mL


What Is NMIBC?

Understanding this type of cancer

The bladder and NMIBC

The bladder is the part of our body where urine is stored. When cancer cells develop and multiply in the bladder, they can form a tumor and spread to other parts of the body.

Non-muscle-invasive bladder cancer (NMIBC) is bladder cancer that has not spread past the lining of the bladder into the muscle. It is the most common type of bladder cancer.



This image shows the inside of the bladder and the different types of tumors that may grow with NMIBC.

Not sure what a term means?
[Click here](#) for a glossary of definitions

Please see **Important Safety Information** on **page 11** and full **Prescribing Information**.

 **ADSTILADRIN**[®]
(nadofaragene firadenovec-vncg)
suspension, for intravesical use / 3×10^{11} viral particles/mL

The Treatment Journey

NMIBC treatment varies based on where a person is on their journey

Bacillus Calmette-Guérin (BCG) is a common first therapy for early-stage bladder cancer that is given directly in the bladder. But sometimes, BCG therapy can stop working, and additional therapy is needed.

If BCG therapy stops working...

There are only a few approved treatment options available to try before bladder removal surgery (a procedure called a cystectomy) is needed.

Bladder removal surgery may cause issues that:

Affect daily life

Change the way the body functions

Impact the ability to pass urine or have sex

But there are reasons to feel hopeful.
ADSTILADRIN (*ad-still-uh-drin*) is a unique treatment that **may help you keep your bladder**

Mike is an actual ADSTILADRIN patient.

Please see Important Safety Information on page 11 and full Prescribing Information.

 **ADSTILADRIN**[®]
(nadofaragene firadenovec-vncg)
suspension, for intravesical use / 3×10^{11} viral particles/mL

What Is ADSTILADRIN?

ADSTILADRIN is the **FIRST** and **ONLY** FDA-approved gene therapy delivered directly in the bladder for high-risk NMIBC

ADSTILADRIN IS...



A localized gene therapy

It causes the immune system to fight NMIBC directly in the bladder.



Given ONCE EVERY 3 MONTHS

This keeps the number of treatment appointments low.



Delivered directly to the bladder

It is given via catheter and stays in the bladder. It doesn't spread throughout the body. This may reduce side effects.



A monotherapy

This means using just one type of medicine to treat a health problem. You do not need to combine ADSTILADRIN with any other medicine for it to work.

You can start this treatment after BCG stops working

You could receive ADSTILADRIN at **REDUCED OR NO COST***
Learn about financial assistance on [page 10](#)

*Terms and conditions apply.

Please see **Important Safety Information** on [page 11](#) and full **Prescribing Information**.

 **ADSTILADRIN**[®]
(nadofaragene firadenovec-vncg)
suspension, for intravesical use / 3×10^{11} viral particles/mL

What Is ADSTILADRIN? (Continued)

ADSTILADRIN IS NOT...



Chemotherapy or BCG treatment

It is an intravesical treatment option that **may help you keep your bladder** if BCG isn't working as it should.



Impacting your entire body

It causes your immune system to attack the cancer in your bladder. It doesn't attack your entire body.



Changing your genes

Instead, it works with your immune system to stop cancer cell growth and kill cancer cells in the bladder.



A treatment that may require you to change doctors

Your doctor may conveniently remain the same since ADSTILADRIN may be given by your urologist in their office.

Learn more about how ADSTILADRIN fights NMIBC at adstiladrin.com/what-is-adstiladrin

Please see Important Safety Information on [page 11](#) and full [Prescribing Information](#).

 **ADSTILADRIN**[®]
(nadofaragene firadenovec-vncg)
suspension, for intravesical use / 3×10^{11} viral particles/mL

STIL EFFECTIVE Out to 5 Years

Clinical study results: ADSTILADRIN was studied in 98 people with high-risk NMIBC whose cancer did not respond to BCG

AT 3 MONTHS




More than half of the people who took ADSTILADRIN had a **complete response** (with no signs of high-grade bladder cancer) after **just 1 dose** (n=50)




AT 1 YEAR

Of the people treated with ADSTILADRIN who had a complete response after just 1 dose:



Nearly half had no signs of high-grade bladder cancer (n=25)



were estimated to **keep their bladder**

Not an actual ADSTILADRIN patient.

Please see **Important Safety Information** on page 11 and **full Prescribing Information**.


 **ADSTILADRIN**[®]
(nadofaragene firadenovec-vncg)
suspension, for intravesical use / 3×10^{11} viral particles/mL

STIL EFFECTIVE Out to 5 Years (Continued)


FROM 2 YEARS OUT TO 5 YEARS

Of the people treated with ADSTILADRIN who had a complete response after just 1 dose:

AT 2 YEARS



More than 1 in 3 people had no signs of high-grade bladder cancer (n=20)



were estimated to keep their bladder

AT 3 YEARS



1 in 4 people had no signs of high-grade bladder cancer (n=14)



were estimated to keep their bladder

OUT TO 5 YEARS



Some people still had no signs of high-grade bladder cancer (n=6)



were estimated to keep their bladder

The longest follow-up of a clinical study for an intravesical BCG-unresponsive high-risk NMIBC treatment



(n=103/107)

OUT TO 5 YEARS

Of the people who received at least 1 dose of ADSTILADRIN, **most did not progress to muscle-invasive bladder cancer**, even if their cancer didn't go away completely (based on results from a TURBT)

Abbreviation: TURBT, transurethral resection of bladder tumor.

Please see Important Safety Information on page 11 and full Prescribing Information.

 **ADSTILADRIN**[®]
(nadofaragene firadenovec-vncg)
suspension, for intravesical use / 3×10^{11} viral particles/mL

STIL HAS A MANAGEABLE SAFETY PROFILE Out to 5 Years

Clinical study results: ADSTILADRIN was studied in 98 people with high-risk NMIBC whose cancer did not respond to BCG

AT 1 YEAR

Most side effects (75%) were mild and went away after a median of **JUST 2 DAYS**.*

- 11% of people had serious side effects

Only 3 out of 98 people had to stop treatment due to side effects.

No deaths occurred due to treatment-related side effects.

- 34% of people interrupted treatment due to side effects but then continued treatment



OUT TO 5 YEARS

0

new side effects were reported

0

deaths due to treatment-related side effects

Not an actual ADSTILADRIN patient.



ADSTILADRIN is a localized treatment. It is NOT chemotherapy

It causes the immune system to attack the cancer in the bladder.
It doesn't attack your entire body.

*Except for fatigue and frequent daytime urination.

Please see Important Safety Information on page 11 and full Prescribing Information.

ADSTILADRIN[®]
(nadofaragene firadenovec-vncg)
suspension, for intravesical use / 3×10^{11} viral particles/mL

STIL CONVENIENT— dosing just **ONCE EVERY 3 MONTHS**

ADSTILADRIN is delivered directly into the bladder through a catheter and may be given by your urologist just like BCG treatment.

Each dosing session will last for at least 1 hour, but you'll be in and out the same day.



You only need to go in for treatment **ONCE EVERY 3 MONTHS**

Your doctor may continue managing your treatment in their office and may conveniently remain the same

After treatment, some common side effects may occur, including:

Urinary
discharge

Urgency to
urinate

Fatigue

Blood in
your urine

Bladder
spasm

These are not all the possible side effects of ADSTILADRIN. Call your doctor for medical advice about side effects if they continue for more than 2 days after treatment. You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects to Ferring Pharmaceuticals at 1-888-337-7464, option 1.



ADSTILADRIN is delivered directly to the bladder (locally) via a catheter

It does not spread throughout the body. This may reduce side effects

Please see Important Safety Information on
[page 11](#) and full [Prescribing Information](#).

 **ADSTILADRIN**[®]
(nadofaragene firadenovec-vncg)
suspension, for intravesical use / 3×10^{11} viral particles/mL

Financial Assistance

Ferring Pharmaceuticals is committed to getting you the resources you need

Ferring Access Support—Patient Assistance Program (PAP):

This program offers patient assistance, coverage support, and other valuable resources for eligible uninsured/underinsured patients, including:

- Referrals to third-party organizations including 501(c)(3) charities, patient support and education groups, and state health exchange resources
- Help with scheduling appointments and staying on top of treatment

You could receive ADSTILADRIN at **REDUCED OR NO COST***

You may contact your healthcare team to help you enroll in the PAP. Learn more at adstiladrin.com/financial-assistance

ADSTILADRIN Copay Program

Eligible, commercially insured patients may **PAY AS LITTLE AS \$100[†]** for each ADSTILADRIN prescription



Learn more about financial assistance programs and if you qualify for savings

Call 1-844-NADOnow
(1-844-623-6669)
Monday to Friday,
9 AM to 6 PM ET

*Terms and conditions apply.

†Available only for patients who meet eligibility requirements. Program does not cover the cost of administration, office visits, or any associated costs. Terms and conditions apply. Offer expires 12/31/24.

Please see Important Safety Information on page 11 and full Prescribing Information.

 **ADSTILADRIN[®]**
(nadofaragene firadenovec-vncg)
suspension, for intravesical use / 3×10^{11} viral particles/mL

Important Safety Information

INDICATION

ADSTILADRIN is a treatment for adults who have all the following:

- High-risk non-muscle-invasive bladder cancer (NMIBC)
- Cancer that is not responding to Bacillus Calmette-Guérin (BCG) therapy
- Carcinoma in situ (CIS) with or without other high-grade tumors

IMPORTANT SAFETY INFORMATION

Who should not receive ADSTILADRIN?

Do not receive ADSTILADRIN if you have a sensitivity to interferon alfa or any of its components.

What is the most important information I should know about ADSTILADRIN?

Individuals who are immunosuppressed or immune-deficient should not prepare, administer, receive or come into contact with ADSTILADRIN.

What should I tell my healthcare provider?

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of ADSTILADRIN?

The most common side effects of ADSTILADRIN include:

Urinary discharge, fatigue, bladder spasm, urgency to urinate, and blood in your urine.

These are not all the possible side effects of ADSTILADRIN. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch or call 1-800-332-1088. You may also contact Ferring Pharmaceuticals at 1-888-FERRING.

What other information should I know about using ADSTILADRIN?

For 2 days following treatment, voided urine should be disinfected for 15 minutes with an equal volume of bleach before flushing.

For more important information, call 1-888-337-7464.

Please see full [Prescribing Information](#).

 **ADSTILADRIN[®]**
(nadofaragene firadenovec-vnccg)
suspension, for intravesical use / 3×10^{11} viral particles/mL

ADSTILADRIN

So You Can **STIL** Do It Your Way



STIL able to **KEEP YOUR BLADDER**

AT 3 MONTHS

- **More than half** of the people who took ADSTILADRIN in a clinical study had a complete response (**with no signs of high-grade bladder cancer**) after just 1 dose (n=50)

OUT TO 5 YEARS

- **Nearly half** of people were estimated to **keep their bladder**
- Some people still had **complete responses out to 5 years** (n=6)
- Of the people who received at least 1 dose of ADSTILADRIN, **most (96%) did not progress to muscle-invasive bladder cancer (n=103/107)**, even if their cancer didn't go away completely (based on results from a TURBT)



STIL HAS A **MANAGEABLE SAFETY PROFILE**

out to 5 years

AT 1 YEAR

- **Most side effects were mild** and went away after a median of **JUST 2 DAYS***
 - 11% of people had serious side effects
 - **Only 3 people** had to stop treatment due to side effects

OUT TO 5 YEARS

- **No new side effects** were reported
- **No deaths occurred** due to treatment-related side effects



STIL CONVENIENT—

dosing just **ONCE EVERY 3 MONTHS**

- **Delivered directly into the bladder** through a urinary catheter
- **May be given and managed by your urologist** in their office

Learn more about **ADSTILADRIN**

Get helpful information and resources, and sign up for updates at adstiladrin.com

*Except for fatigue and frequent daytime urination.

Please see Important Safety Information on page 11 and full Prescribing Information.



©2024 Ferring. ADSTILADRIN, Ferring and the Ferring Pharmaceuticals logo are trademarks of Ferring.
US-ADST-2400171 v1 09/24

 **ADSTILADRIN**[®]
(nadofaragene firadenovec-vncg)
suspension, for intravesical use / 3 x 10¹¹ viral particles/mL